1. Jenks JD, Cornely OA, Chen SC, Thompson GR, 3rd, Hoenigl M. Breakthrough invasive fungal infections: Who is at risk? Mycoses. 2020;63:1021-32.
2. Hoenigl M, Arastehfar A, Arendrup MC, Brüggemann R, Carvalho A, Chiller T, et al. Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal
disease. Clin Microbiol Rev. 2024;37:e0007423.
3. Rex JH, Pfaller MA. Has antifungal susceptibility testing come of age? Clin Infect Dis. 2002;35:982-989.
4. Ullmann AJ, Aguado JM, Arikan-Akdagli S, Denning DW, Groll AH, Lagrou K, et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-EC-
MM-ERS guideline. Clin Microbiol Infect. 2018;24 Suppl 1:e1-e38.
5. Cuenca-Estrella M, Verweij PE, Arendrup MC, Arikan-Akdagli S, Bille J, Donnelly JP, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic
procedures. Clin Microbiol Infect. 2012;18 Suppl 7:9-18.
6. Caplan AS, Todd GC, Zhu Y, Sikora M, Akoh CC, Jakus J, et al. Clinical Course, Antifungal Susceptibility, and Genomic Sequencing of Trichophyton indotineae. JAMA Dermatol. 2024;160:701-
709.
7. Gaurav V, Bhattacharya SN, Sharma N, Datt S, Kumar P, Rai G, et al. Terbinafine resistance in dermatophytes: Time to revisit alternate antifungal therapy. J Mycol Med. 2021;31:101087.
8. Sanguinetti M, Posteraro B. New approaches for antifungal susceptibility testing. Clin Microbiol Infect. 2017;23:931-934.
9. Nnadi NE, Carter DA. Climate change and the emergence of fungal pathogens. PLoS Pathog. 2021;17(4):e1009503.
10. Hoenigl M, Sprute R, Egger M, Arastehfar A, Cornely OA, Krause R, et al. The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin. Drugs.
2021;81:1703-1729.
11. Ben-Ami R, Kontoyiannis DP. Resistance to Antifungal Drugs. Infect Dis Clin North Am. 2021;35:279-311.
12. Clinical and Laboratory Standards Institute. Method for Antifungal Disk Diffusion Susceptibility Testing of Yeasts; 3rd ed. CLSI Guideline M44. Wayne, PA, 2018.
13. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. 4th ed. CLSI Standard M27. Wayne, PA, 2017.
14. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi. 3rd ed. CLSI Standard M38. Wayne, PA, 2017.
15. European Committee on Antimicrobial Susceptibility Testing. Guinea J, Meletiadis J, Arikan-Akdagli S, Giske C, Muehlethaler K, Arendrup MC and the Subcommittee on Antifungal Suscep-
tibility Testing (AFST) of the ESCMID European Committee on Antimicrobial Susceptibility Testing (EUCAST). EUCAST Definitive Document E.DEF 7.4 Method for the determination of
broth dilution minimum inhibitory concentrations of antifungal agents for yeasts Available: https://www.eucast.org/fungi-afst/methodology-and-instructions/ast-of-yeasts/2023.
16. European Committee for Antimicrobial Susceptibility Testing (EUCAST). Guinea J, Meletiadis J, Arikan-Akdagli S, Muehlethaler K, Kahlmeter K, Arendrup MC and the Subcom-
mittee on Antifungal Susceptibility Testing (AFST) of the ESCMID EUCAST. EUCAST Definitive Document E.DEF 9.4 Method for the determination of broth dilution minimum
inhibitory concentrations of antifungal agents for conidia forming moulds. .Available https://www.eucast.org/fungi-afst/methodology-and-instructions/ast-of-moulds/2022.
17. Franconi I, Lupetti A. In Vitro Susceptibility Tests in the Context of Antifungal Resistance: Beyond Minimum Inhibitory Concentration in Candida spp. J Fungi. 2023;9: 1188.
18. Chen SC, Perfect J, Colombo AL, Cornely OA, Groll AH, Seidel D, et al. Global guideline for the diagnosis and management of rare yeast infections: an initiative of the ECMM in cooperation
with ISHAM and ASM. Lancet Infect Dis. 2021;21:e375-e386.
19. Chang CC, Harrison TS, Bicanic TA, Chayakulkeeree M, Sorrell TC, Warris A, et al. Global guideline for the diagnosis and management of cryptococcosis: an initiative of the ECMM and
ISHAM in cooperation with the ASM. Lancet Infect Dis. 2024;24:e495-e512.
20. Hoenigl M, Salmanton-García J, Walsh TJ, Nucci M, Neoh CF, Jenks JD, et al. Global guideline for the diagnosis and management of rare mould infections: an initiative of the Europe-
an Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology. Lancet Infect Dis.
2021;21(8):e246-e57.
21. Carvalhaes C. When Should Antifungal Susceptibility Testing Be Performed For Candida Species Isolated From Clinical Specimens? https://clsi.org/about/news/ast-news-update-2019-prac-
tical-tips-1/: Clinical and Laboratory Standards Institute; 2019.
22. Espinel-Ingroff A, Arendrup MC, Pfaller MA, Bonfietti LX, Bustamante B, Canton E, et al. Interlaboratory variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST met-
hods: should the clinical laboratory be testing this agent? Antimicrob Agents Chemother. 2013;57:5836-5842.
23. Patterson TF, Thompson GR, 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, et al. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infec-
tious Diseases Society of America. Clin Infect Dis. 2016;63:e1-e60.
24. European Committee on Antimicrobial Susceptibility Testing. Meletiadis J GJ, Arikan-Akdagli S, Friberg N, Kahlmeter G, Arendrup MC and the Subcommittee on Antifungal Susceptibility
Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST). EUCAST Definitive Document E.DEF 10.2 Screening method for the detection of
azole and echinocandin resistance in Aspergillus using antifungal-containing agar plates, exemplified by A. fumigatus: Available https://www.eucast.org/fungi-afst/methodology-and-instru-
ctions/ast-of-moulds/; 2022.
25. Siopi M, Efstathiou I, Arendrup MC, Meletiadis J. Development of an agar-based screening method for terbinafine, itraconazole, and amorolfine susceptibility testing of Trichophyton spp. J
Clin Microbiol. 2024;62(1):e0130823.
26. Clinical and Laboratory Standards Institute. Method for Antifungal Disk Diffusion Susceptibility Testing of Nondermatophyte Filamentous Fungi; Approved Guideline. CLSI Document
M51-A. Wayne, PA, 2010.
27. Arendrup MC, Kahlmeter G, Guinea J, Meletiadis J. How to: perform antifungal susceptibility testing of microconidia-forming dermatophytes following the new reference EUCAST method
E.DEF 11.0, exemplified by Trichophyton. Clin Microbiol Infect. 2021;27:55-60.
28. Clinical and Laboratory Standards Institute. Performance Standards of Antifungal Susceptibility Testing of Filamentous Fungi. 3rd ed. CLSI Supplement M38M51S. Clinical and Laboratory
Standards Institute, 2022.
29. Clinical and Laboratory Standards Institute. Performance Standards for Antifungal Susceptibility Testing of Yeasts. 3rd ed. CLSI Supplement M24M44S, 2022.
30. Clinical and Laboratory Standards Institute. Epidemiological Cutoff Values for Antifungal Susceptibility Testing. 4th ed. CLSI supplement M57S. Clinical and Laboratory Standards Institute,
2022.
31. The European Committee on Antimicrobial Susceptibility Testing (EUCAST). Fungi (AFST). www.eucast.org.
32. Astvad KMT, Arikan-Akdagli S, Arendrup MC. A Pragmatic Approach to Susceptibility Classification of Yeasts without EUCAST Clinical Breakpoints. J Fungi. 2022;8: 141.
33. Durand C, Maubon D, Cornet M, Wang Y, Aldebert D, Garnaud C. Can We Improve Antifungal Susceptibility Testing? Front Cell Infect Microbiol. 2021;11:720609.
34. Berkow EL, Lockhart SR, Ostrosky-Zeichner L. Antifungal Susceptibility Testing: Current Approaches. Clin Microbiol Rev. 2020;33:e00069-19.
35. Cuenca-Estrella M, Gomez-Lopez A, Alastruey-Izquierdo A, Bernal-Martinez L, Cuesta I, Buitrago MJ, et al. Comparison of the Vitek 2 antifungal susceptibility system with the clinical and
laboratory standards institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) Broth Microdilution Reference Methods and with the Sensititre YeastOne
and Etest techniques for in vitro detection of antifungal resistance in yeast isolates. J Clin Microbiol. 2010;48:1782-1786.
36. Alexander BD, Byrne TC, Smith KL, Hanson KE, Anstrom KJ, Perfect JR, et al. Comparative evaluation of Etest and sensititre yeastone panels against the Clinical and Laboratory Standards
Institute M27-A2 reference broth microdilution method for testing Candida susceptibility to seven antifungal agents. J Clin Microbiol. 2007;45:698-706.
37. Bélik F, Deckers C, Khourssaji M, Huang TD, Denis O, Montesinos I. Comparative assessment of Sensititre YeastOne and Micronaut-AM EUCAST for antifungal susceptibility testing in
candidaemia isolates. J Mycol Med. 2024;34:101465.
38. Philips S, Van Hoecke F, De Laere E, Vervaeke S, De Smedt R, Boelens J, et al. Comparison of Two Commercial Colorimetric Broth Microdilution Tests for Candida Susceptibility Testing:
Sensititre YeastOne versus MICRONAUT-AM. J Fungi. 2021;7: 356.
39. Simitsopoulou M, Chatzimoschou A, Roilides E. Biofilms and Antifungal Susceptibility Testing. Methods Mol Biol. 2016;1356:183-197.
40. Vale-Silva LA, Buchta V. Antifungal susceptibility testing by flow cytometry: is it the future? Mycoses. 2006;49:261-73.
41. Arthington-Skaggs BA, Warnock DW, Morrison CJ. Quantitation of Candida albicans ergosterol content improves the correlation between in vitro antifungal susceptibility test results and in
vivo outcome after fluconazole treatment in a murine model of invasive candidiasis. Antimicrob Agents Chemother. 2000;44:2081-2085.
42. Arthington-Skaggs BA, Lee-Yang W, Ciblak MA, Frade JP, Brandt ME, Hajjeh RA, et al. Comparison of visual and spectrophotometric methods of broth microdilution MIC end point deter-
mination and evaluation of a sterol quantitation method for in vitro susceptibility testing of fluconazole and itraconazole against trailing and nontrailing Candida isolates. Antimicrob Agents
Chemother. 2002;46:2477-2481.
43. Arendrup MC, Guinea J, Meletiadis J. Twenty Years in EUCAST Anti-Fungal Susceptibility Testing: Progress & Remaining Challenges. Mycopathologia. 2024;189:64